ClinicalTrials.gg
CompletedNCT00939731Updated Oct 24, 2011Results posted

Relative Drug Exposures Of Two Formulations of PF-02341066

A Phase 1 interventional study of PF-02341066 and PF-02341066 in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-24.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over, single-dose study employing administration of two PF-02341066 formulations in the fasted state to healthy adult volunteers.

02

Conditions studied

  • Healthy

Keywords

  • bioavailability, capsule, tablet, healthy volunteer
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female of non- subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead (ECG) and clinical laboratory tests).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Treatment with an drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
  • Pregnant or nursing females; females of , including those with tubal ligation. To be considered for enrollment, women of 45 to 55 years of age who are (defined as being amenorrheic for at least 2 years) must have confirmatory Follicle-stimulating hormone(FSH) test results at Screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    PIC

    Drug: PF-02341066

  • Experimental
    IRT

    Drug: PF-02341066

Interventions

  • A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules

  • A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hours (hrs) post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2

  3. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2

  2. Plasma Decay Half Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2

  3. Apparent Oral Clearance (CL/F)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2

  4. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2

07

Results

Posted Oct 18, 2011

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestonePF-02341066 250 mg IRT First, Then PF-02341066 250 mg PICPF-02341066 250 mg PIC First, Then PF-02341066 250 mg IRT
Started1212
Completed1212
Not completed00
Washout Period (at Least 14 Days)
Participant flow — Washout Period (at Least 14 Days)
MilestonePF-02341066 250 mg IRT First, Then PF-02341066 250 mg PICPF-02341066 250 mg PIC First, Then PF-02341066 250 mg IRT
Started1212
Completed1212
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestonePF-02341066 250 mg IRT First, Then PF-02341066 250 mg PICPF-02341066 250 mg PIC First, Then PF-02341066 250 mg IRT
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hours (hrs) post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLPF-02341066 250 mg PICPF-02341066 250 mg IRT
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)2804.5 ± 941.42597.3 ± 924.1
Statistical analysis
  • PF-02341066 250 mg PIC vs PF-02341066 250 mg IRT · Ratio of adjusted means: 92.61 · 90% CI 84.84 to 101.09
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrPF-02341066 250 mg PICPF-02341066 250 mg IRT
Time to Reach Maximum Observed Plasma Concentration (Tmax)6.00 (2.00 to 8.00)6.00 (2.00 to 8.00)
SecondaryPlasma Decay Half Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2)
hrPF-02341066 250 mg PICPF-02341066 250 mg IRT
Plasma Decay Half Life (t1/2)29.48 ± 4.6229.10 ± 4.66
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])
ng*hr/mLPF-02341066 250 mg PICPF-02341066 250 mg IRT
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])2945.5 ± 955.22722.5 ± 939.2
Statistical analysis
  • PF-02341066 250 mg PIC vs PF-02341066 250 mg IRT · Ratio of adjusted means: 92.43 · 90% CI 84.86 to 100.68
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLPF-02341066 250 mg PICPF-02341066 250 mg IRT
Maximum Observed Plasma Concentration (Cmax)113.35 ± 34.22112.11 ± 34.87
Statistical analysis
  • PF-02341066 250 mg PIC vs PF-02341066 250 mg IRT · Ratio of adjusted means: 98.91 · 90% CI 90.18 to 108.48
SecondaryApparent Oral Clearance (CL/F)

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F)
L/hrPF-02341066 250 mg PICPF-02341066 250 mg IRT
Apparent Oral Clearance (CL/F)84.9 ± 31.691.8 ± 35.8
SecondaryApparent Volume of Distribution (Vz/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, 84 and 96 hrs post PF-02341066 dose in period 1 and additional 168 hrs post PF-02341066 dose in period 2
Reported as:
Geometric mean · L
Apparent Volume of Distribution (Vz/F)
LPF-02341066 250 mg PICPF-02341066 250 mg IRT
Apparent Volume of Distribution (Vz/F)3566.8 ± 1820.53809.3 ± 1784.4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-02341066 250 mg PIC—0/24 (0%)7/24 (29.2%)
PF-02341066 250 mg IRT—0/24 (0%)8/24 (33.3%)
Most frequent other events
Most frequent other events
EventPF-02341066 250 mg PICPF-02341066 250 mg IRT
NauseaGastrointestinal disorders3/244/24
DiarrhoeaGastrointestinal disorders1/243/24
FatigueGeneral disorders1/241/24
Seborrhoeic dermatitisSkin and subcutaneous tissue disorders1/241/24
Abdominal tendernessGastrointestinal disorders1/240/24
FlatulenceGastrointestinal disorders1/240/24
ExcoriationInjury, poisoning and procedural complications1/240/24
DizzinessNervous system disorders0/241/24
HeadacheNervous system disorders1/240/24
SomnolenceNervous system disorders0/241/24

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean32.1 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male24
08

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2009
First posted
Jul 15, 2009
Start
Jul 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Oct 18, 2011
Last update
Oct 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00939731
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 15, 2009
Start date
Jul 2009
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Oct 18, 2011
Last update
Oct 24, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion